Instrument Inactif

Communiqués Integrity Applications, Inc. Other OTC

Actions

IGAP

US45824Q1013

Recherche biotechnologique et médicale

Communiqués

14:03	Lokahi Therapeutics Initiates Clinical Trial Manufacturing for LT-100	AQ
25/08	Lōkahi Therapeutics™ Initiates Clinical Trial Manufacturing for LT-100	BU
24/08	Lokahi Therapeutics Expands ai-2 Futures Lab Asset Origination Network Through Continued Collaboration with the University of Georgia	AQ
21/08	Lōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Continued Collaboration with the University of Georgia	BU
17/08	Glucotrack Achieves Key Compliance Milestone and Advances Strategic Transformation	BU
06/08	E.F. Hutton & Co. Acts as Exclusive Financial Advisor for $5.5 Million Financing for Glucotrack	AQ
05/08	Glucotrack Announces $5.5 Million Financing	BU
03/08	Lokahi Therapeutics ai-2 Futures Lab Changes How Biopharma Builds a Pipeline	AQ
31/07	CORRECTING and REPLACING Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a Pipeline	BU
30/07	Lokahi Therapeutics Advances LT-100 Development Strategy toward Single-Injection Administration	AQ
29/07	Lōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection Administration	BU
17/07	E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million Convertible Note Financing	AQ
17/07	Glucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets Initiatives	AQ
16/07	GlucoTrack : UPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform	PU
15/07	Glucotrack and Lokahi Therapeutics Complete Strategic Business Combination, Establishing Lokahi-Controlled Public Platform	AQ
14/07	Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform	AQ
08/07	Glucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM Platform	AQ
26/05	Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association’s 2026 Scientific Sessions	AQ
14/05	Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights	AQ
07/05	Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology	AQ
30/04	Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology	AQ
21/04	Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology	AQ
30/03	Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights	AQ
27/03	Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones	AQ
10/03	Glucotrack to Present at LSI USA ’26 Medtech Innovation Summit	AQ